Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 9/20 | 0.44 |
| ▸ | DRD2 | P14416 | 8/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4790927 | 0.88 | HRH3 (0.47) | HRH3DRD3DRD2 | |
| SCHEMBL4773893 | 0.85 | HTR2C (0.53) | HRH3DRD3DRD2 | |
| SCHEMBL5098547 | 0.83 | HTR2C (0.58) | HRH3 | |
| SCHEMBL4771909 | 0.81 | HRH3 (0.55) | HRH3DRD3DRD2 | |
| SCHEMBL10158484 | 0.80 | PNMT (0.56) | HRH3PNMTDRD3DRD2 | |
| SCHEMBL4770231 | 0.80 | HTR2C (0.60) | PNMT | |
| SCHEMBL4564593 | 0.75 | DRD3 (0.42) | HRH3PNMTDRD3DRD2 | |
| SCHEMBL1958497 | 0.74 | DRD2 (0.44) | HRH3PNMTDRD3DRD2 | |
| SCHEMBL14297366 | 0.74 | PNMT (0.53) | PNMTDRD3DRD2 | |
| SCHEMBL4387090 | 0.73 | HTR2C (0.55) | PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429579-B2 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM, PLC (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1335915-B1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2008-01-02 | — | — | EP | disclosed |
| US-20040171606-A1 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM PLC (GB) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171606-A1 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | DRD3, DRD2, DRD1 | HRH3 312/4885PNMT 742/4885DRD3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.